Introduction
Infection with human herpesvirus 6 (HHV-6) is ubiquitous: primary infection usually occurs by the salivary route in early childhood, and the virus then latently persists lifelong. Primary infection in childhood is usually clinically silent or associated with a mild febrile illness including exanthem subitum. Increasingly, however, viral reactivation with clinically significant manifestations such as bone marrow suppression or encephalitis is being recognized in immunocompromised patients, particularly stem cell transplant recipients.
1,2 There is, however, an alternative form of HHV-6 persistence that occurs in a subgroup of individuals, which is characterized by very high viral loads in blood (41 Â 10 6 HHV-6 genomes/ml) 3-5 and other bodily fluid or tissue samples and is due to chromosomal-integration (CI) of the HHV-6 genome. Growing evidence suggests that these integrated viral sequences have been inherited through the germ line and are therefore present in every nucleated cell. This phenomenon may confound the laboratory diagnosis of active HHV-6 infection, as whole blood, plasma, serum and CSF from individuals with viral integration are persistently positive for HHV-6 DNA even in the absence of independent viral replication.
3-6 The prevalence of HHV-6 integration is not clearly defined but has been placed at between 1 and 3% in the United Kingdom, 7 although one report suggests it may be lower in Japan. 8 The clinical significance, if any, of HHV-6 integration is not known, and although the integrated genome may be transcriptionally active, 9 to date no replication has been shown from the integrated sequences in vitro or in vivo. 8, 10, 11 As has recently been reported, 3,4 transmission of the CI HHV-6 genome by stem cell transplantation from donor to recipient could be misinterpreted as active HHV-6 infection, prompting unnecessary anti-viral therapy. We here report two further cases of transmission of CI HHV-6 in the course of allogeneic hematopoietic stem cell transplantation and discuss its manifestations and management.
Patients and methods

Patients and treatments
The study was approved by our Institutional Review Board (IRB). Patient's clinical and laboratory details are summarized in Table 1 . Both patients (29-and 49-year-old) had acute lymphoblastic leukemia in first complete remission. The conditioning regimen for transplant included cyclophosphamide and total body irradiation (1200 cGy). Both patients received unmanipulated bone marrow grafts with 43.0 Â 10 6 /kg CD34 þ cells from related family donors.
GVHD prophylaxis consisted of short-course methotrexate (5 mg/m 2 on days þ 1, þ 3 and þ 6) and tacrolimus. Viral prophylaxis consisted of acyclovir (500 mg twice a day). Engraftment was defined as neutrophils 4500 cells/ml and platelets 420 000 cells/ml (in the absence of transfusion) for three consecutive days. GVHD was defined and graded according to standard criteria. 12 Standard post-transplant viral screening included CMV (antigenemia and quantitative PCR) and HHV-6 and BK virus by quantitative PCR. Clinically significant HHV-6 infection was defined as evidence of rash, bone marrow suppression or neurologic manifestations in the absence of any other identifiable etiology.
Laboratory evaluation of HHV-6 HHV-6 serology. Recipient HHV-6 serology was obtained pre-transplant, and IgG and IgM antibodies to HHV-6 were measured by immunofluorescence assay (ARUP Laboratories, Salt Lake, UT, USA). 13 Plasma and whole blood PCR amplification for HHV6 DNA was performed as previously described (Viracor, Lee's Summit, MO, USA).
14 Initial analysis was performed at engraftment, and if positive, HHV-6 PCR was performed weekly for 6-8 weeks; in the absence of clinically significant HHV-6 infection, the frequency of evaluation was reduced to every 2-4 weeks. We do not routinely perform HHV-6 analyses of the donors.
Evaluation of chromosomally integrated HHV-6. Hair samples were obtained from the donor of patient 1 and DNA extracted from the proximal 0.5-1 cm of each hair follicle using QuickExtract DNA Extraction Solution (Epicenter, Madison, WI, USA) as previously described. 5 Extracts were tested using quantitative PCR for HHV-6, which targets the U67 gene and is present as one copy per viral genome, 3 and human b-globin DNA, 15 which is present as two copies per diploid cell. HHV-6 copies/cell was determined by dividing the HHV-6 viral load by half of the b-globin load.
5-7
Results
Patient, disease and transplant characteristics are detailed in Table 1 . Both recipients had positive serology for HHV-6-IgG suggesting earlier exposure. In patient 1, pre-transplant HHV-6 plasma PCR was negative. Pretransplant PCR was unavailable for patient 2. Positive HHV-6 PCR was first evident at neutrophil engraftment (day 19 both patients) when 3600 and 15 400 DNA copies/ml were detected in the plasma of patients 1 and 2 respectively (Table 1 ) Whole blood HHV-6 analysis revealed 6.1 Â 10 6 and 9.7 Â 10 5 DNA copies/ml (Table 1) . Because such high titers of viral DNA were found at the time of engraftment and because clinical symptoms were absent, we considered whether the high viral DNA measures were due to transmission of integrated HHV-6 from the stem cell donors. Comparison of whole blood versus plasma HHV-6 DNA levels supported this possibility. Plasma PCR was elevated to 5.6 Â 10 4 and 1.3 Â 10 5 DNA copies/ ml, respectively, in donor 1 and 2, while whole blood HHV-6 levels were strikingly elevated at 4.1 Â 10 6 and 4.7 Â 10 6 DNA copies/ml, respectively. The whole blood HHV-6 DNA levels paralleled total white cell count in both patients (Figures 1 and 2) . In patient 1, we also traced HHV-6 integration to his mother (biological mother of the patient and donor) who had 4000 HHV-6 DNA copies/ml in her plasma and 3.8 Â 10
6 DNA copies/ml in her whole blood. Using real-time quantitative PCR of HHV-6, B10
4 copies of HHV-6 genome were present per hair follicle in patient 1 donor's hair sample. This was X1 copy HHV-6/cellular equivalent of DNA. This result is consistent with the diagnosis of chromsomally integrated HHV-6.
The serial plasma and whole blood HHV-6 PCR performed at weekly or biweekly intervals for 20 weeks after engraftment in both patients (Figures 1 and 2) was consistent with the persistence of an integrated viral genome. Transmission of integrated HHV-6 through donor cells did not influence transplant outcome, and both the patients had uneventful post transplant courses. 
Discussion
These results confirm the occurrence of donor-to-recipient transmission of CI HHV-6. Transmission is manifest by higher whole blood than plasma HHV-6 DNA occurring at the time of engraftment. Transmission of integrated HHV-6 was not associated with clinical disease and did not adversely influence transplant outcome. The origin of the integrated viral sequences was traced to the mother of one patient. Confirmation of CI HHV-6 precluded unnecessary antiviral therapy. Clark et al. 3 reported a hemopoietic stem cell transplant in which a stem cell donor with CI HHV-6 transmitted the viral sequences to a recipient who had been negative for HHV-6 by PCR and had no evidence for HHV-6 integration before transplant. In this patient, the appearance and subsequent increase in the HHV-6 DNA load paralleled engraftment and increase in white cell counts. A FISH analysis confirmed integrated HHV-6 on chromosome band 17p13.3 in the recipient post transplant but not pre-transplant. Viral transmission was asymptomatic and did not influence transplant outcome. Continued follow-up is needed as the natural history of iatrogenic HHV-6 transmission is poorly documented.
Recent reports suggest that positive HHV-6 plasma DNA occurs in half of the allogeneic transplant recipients.
2, 16 The probability of HHV-6 positivity (assessed by PCR) is increased by the use of allelic mismatch transplant and the administration of steroids.
2, 16 Clinically significant infection occurs only in a minority of patients; in the absence of unambiguous data, probably fewer than 3% of the patients develop clinically significant organ dysfunction. 17 Since plasma HHV-6 PCR is positive in half of the hematopoietic transplant recipients, but causes disease in less than 3%, there is a need to exclude other pathogens and pathologies before diagnosing HHV-6 disease after stem cell transplantation. The confirmation of donorto-recipient transmission of CI HHV-6 through hematopoietic transplant further confounds interpretation of positive HHV-6 PCR. Screening of healthy blood donors in the United Kingdom 7 showed that 0.8% of the general population may have CI HHV-6, so that such donorto-recipient transmission is likely to occur with a similar frequency.
How may CI HHV-6 may be distinguished from viral reactivation or disease? We now know that the median time to positive plasma HHV-6 PCR from the transplant is 3 weeks (coinciding with neutrophil engraftment) 2, 16 and that the median maximum plasma HHV-6 DNA load in those with positive PCR was 138 and 3278 copies/ml in two recent studies.
2, 16 The whole blood HHV-6 levels in the presence of CI HHV-6 is 50 to 100 fold higher compared to plasma. 5 Estimation of whole blood HHV-6 PCR therefore readily allows differentiation of CI HHV-6 from true viral reactivation. Demonstration of strikingly high levels of HHV-6 DNA in whole blood samples will strongly suggest the presence of integrated HHV-6. Since integration of HHV-6 and its transmission may occur with significant frequency, it is possible that there has been an overestimation of clinically significant HHV-6 infection in transplant recipients, and distinction between these two phenomena is essential to avoid unnecessary anti-viral therapy. 
